EUVIMEDEUVIMED entdecken
Open Access

Low-Voltage Area Ablation for Persistent Atrial Fibrillation

Pablo B Nery, George A Wells, Girish M Nair, Vidal Essebag, Jacqueline Joza, Jorge A Wong, George D Veenhuyzen, Atul Verma, Isabelle Nault, Jason Andrade, John L Sapp, Allan Skanes und 14 weitere

JAMA · 08.11.2026

DOI: 10.1001/jama.2026.24331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, online erschienen am 08.11.2026. Verfasst von Pablo B Nery und 25 weiteren Autor:innen. Beteiligte Einrichtung: University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Pulmonary vein isolation (PVI) for persistent atrial fibrillation (AF) has demonstrated modest success rates. Ablation of atrial low-voltage areas (LVA) has shown potential results, but more data are required.

Objective

To determine whether PVI plus LVA ablation is superior to PVI alone in reducing atrial arrhythmia recurrence in patients with AF. Design, Setting, and Participants Single-blind randomized clinical trial in 14 AF ablation centers in Canada. Adults with persistent AF of more than 3 months were enrolled between August 2018 and September 2024 and followed up for 18 to 36 months through April 2026.

Intervention

Patients were randomized to PVI plus LVA ablation or PVI alone. Main Outcomes and Measures The primary outcome was atrial arrhythmia recurrence beyond 90 days after a single catheter ablation procedure. Secondary outcomes included repeat ablation for AF, atrial flutter, or atrial tachycardia, emergency visits or hospitalization, arrhythmia recurrence over 18 months, procedure duration, total ablation delivery time, AF burden, and safety outcomes. The primary efficacy analysis was based on the modified intention-to-treat principle for patients who received the intervention.

Results

Among 508 enrolled patients, 253 were randomized to PVI plus LVA ablation and 255 to PVI alone. Mean (SD) age was 65.2 (9.0) years, 386 (76%) were male and 268 (54%) had LVA. After a mean (SD) follow-up of 21 (15) months, 124 (49.4%) randomized to PVI plus LVA and 146 (57.5%) randomized to PVI reached the primary outcome (hazard ratio [HR], 0.82; 95% CI, 0.65-1.04; P = .11). In the prespecified principal subgroup analysis of 268 patients with LVA, arrhythmia recurrence occurred in 68 of 138 patients (49.3%) following PVI plus LVA ablation compared with 90 of 130 patients (69.2%) following PVI alone (HR, 0.77; 95% CI, 0.66-0.91; P = .002). Arrhythmia recurrence over 18 months (37.0% vs 56.2%; HR, 0.77; 95% CI, 0.64-0.92) and AF burden were lower after PVI plus LVA ablation in this group. Among patients without LVA, recurrence was similar between ablation groups (56 of 113 [49.6%] vs 51 of 113 [45.1%]; HR, 1.09; 95% CI, 0.90-1.32). Procedure duration and ablation delivery time were longer in the PVI plus LVA ablation group. Safety outcomes were similar between groups. Conclusions and Relevance In this study, among patients with persistent AF, adjunctive LVA ablation did not significantly reduce atrial arrhythmia recurrence in the overall population over a mean 21-month follow-up. A prespecified principal subgroup analysis of patients with LVA suggested that adjunctive LVA ablation was consistent with reduced recurrence of atrial arrhythmias in this group. Trial Registration ClinicalTrials.gov, Identifier: NCT03347227

Autor:innen und Institutionen

  • University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
  • School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
  • McGill University Health Centre, Montreal, Quebec, Canada.
  • McMaster University, Population Health Research Institute, Hamilton, Ontario, Canada.
  • Libin Cardiovascular Institute, Calgary, Alberta, Canada.
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, Quebec, Canada.

Zitieren

APA

Nery, P. B., Wells, G. A., Nair, G. M., Essebag, V., Joza, J., Wong, J. A., Veenhuyzen, G. D., Verma, A., Nault, I., Andrade, J., Sapp, J. L., Skanes, A., Golian, M., Macle, L., Sadek, M., Angaran, P., Sikkel, M., Dussault, C., Yung, D., …, & Birnie, D. H. (2026). Low-Voltage Area Ablation for Persistent Atrial Fibrillation. JAMA. https://doi.org/10.1001/jama.2026.24331

Vancouver

Nery PB, Wells GA, Nair GM, Essebag V, Joza J, Wong JA, et al. Low-Voltage Area Ablation for Persistent Atrial Fibrillation. JAMA. 2026. doi:10.1001/jama.2026.24331

BibTeX
@article{Nery2026,
  author = {Nery, Pablo B and Wells, George A and Nair, Girish M and Essebag, Vidal and Joza, Jacqueline and Wong, Jorge A and Veenhuyzen, George D and Verma, Atul and Nault, Isabelle and Andrade, Jason and Sapp, John L and Skanes, Allan and Golian, Mehrdad and Macle, Laurent and Sadek, Mouhannad and Angaran, Paul and Sikkel, Markus and Dussault, Charles and Yung, Derek and Healey, Jeff S and Hansom, Simon and Redpath, Calum J and Redfearn, Damian and Ramirez, F Daniel and Klein, Andres and Birnie, David H},
  title = {Low-Voltage Area Ablation for Persistent Atrial Fibrillation},
  journal = {JAMA},
  year = {2026},
  doi = {10.1001/jama.2026.24331}
}
Kostenlos starten →